Sarepta Therapeutics

Yahoo Finance • 6 days ago

How Do Sarepta (SRPT)’s Enhanced Safety Moves Reflect Its Approach to Long-Term Risk Management?

Earlier this week, Sarepta Therapeutics received FDA approval to begin dosing non-ambulant Duchenne muscular dystrophy patients in Cohort 8 of the ENDEAVOR study, evaluating an enhanced immunosuppression regimen with Elevidys, and announce... Full story

Yahoo Finance • 9 days ago

Trump Media and 11 More Stocks to Avoid Until 2026

Investors should be extra cautious when thinking about being contrarians and buying losers at the end of any calendar year. Continue Reading View Comments... Full story

Yahoo Finance • 20 days ago

Sarepta gene therapy Elevidys gets FDA Boxed Warning following two patient deaths

[Alphabet letter in word FDA (abbreviation of food and drug administration) on wood background] bankrx * The US FDA has ordered a Boxed Warning be added to the labeling of Sarepta Therapeutics' (SRPT [https://seekingalpha.com/symbol/SRP... Full story

Yahoo Finance • 20 days ago

Sector Update: Health Care Stocks Ease Late Afternoon

Health care stocks fell late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Hea PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 30 days ago

The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following ESSENCE Trial Miss and FDA Discussions

On November 3, 2025, Sarepta Therapeutics reported that its Phase 3 ESSENCE trial for Duchenne muscular dystrophy therapies AMONDYS 45 and VYONDYS 53 did not meet the primary endpoint, though numerical trends favored the treatments and saf... Full story

Yahoo Finance • 30 days ago

Sarepta Loses A Third Of Its Value On Failed Tests, Gene Therapy Outlook

Sarepta stock crashed Tuesday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests. Continue Reading View comments... Full story

Yahoo Finance • 30 days ago

Stocks making the biggest moves midday: Uber, Hertz, Norwegian Cruise, Yum, Palantir and more

Check out the companies making the biggest moves midday: Denny's — The diner chain rallied 50% after it announced it would be acquired by private equity firm TriArtisan Capital Advisors for $620 million, or $6.25 per share, in cash. The de... Full story

Yahoo Finance • last month

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

CAMBRIDGE, Mass., October 27, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2025 financial results after the Nasdaq Global Market clos... Full story

Yahoo Finance • 2 months ago

Duchenne Muscular Dystrophy Drugs Market Global Forecast 2025-2032: Sarepta, Pfizer, BioMarin, Roche, Bayer, Solid Biosciences, Cytokinetics, and NS Pharma Drive Innovation and Commercial Expansion

Company Logo The Duchenne Muscular Dystrophy Drugs Market presents opportunities in advanced genetic therapies, digital health, and adaptive models amid rising global demand. Strategic alliances, resilient supply chains, and localized str... Full story

Yahoo Finance • 2 months ago

Advanced Viral Delivery Systems Revolutionizing Gene Therapy for Neurological Disorders

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy on Neurological Diseases Market Report 2025" has been added to ResearchAndMarkets.com's offering. The gene therapy on neurological diseases market size has grown rapidly in... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves midday: Starbucks, FICO, Acadia Healthcare & more

Check out the companies making the biggest moves midday: Acadia Healthcare — The healthcare stock jumped about 7% after investors Khrom Capital filed to push the company to explore strategic alternatives. Acadia shares are down 33% year to... Full story

Yahoo Finance • 2 months ago

Aurinia responds after top FDA official’s comment on lead drug

[US Food and Drug Administration (FDA)] Aurinia Pharmaceuticals (NASDAQ:AUPH [https://seekingalpha.com/symbol/AUPH]) traded ~7% higher in the premarket on Tuesday after the company responded to a comment made by a top FDA regulator regard... Full story

Yahoo Finance • 2 months ago

Roche Shares Dip 4% as Pharma Tariff Decision Looms: What Is the Stock Really Worth?

If you own Roche Holding stock or are weighing whether now is the right time to step in, you are not alone. The recent price action has certainly caught the eye of investors. Roche’s shares closed at 253.5, down 4.4% over the past week and... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest moves midday: Oracle, Apple, Metsera, Compass, Kenvue and more

Check out the companies making headlines in midday trading : Better Home & Finance Holding — The mortgage lender briefly soared as much as 176% Monday after hedge fund manager Eric Jackson in a social media post on X called Better Home "th... Full story

Yahoo Finance • 2 months ago

Stocks making the biggest premarket moves: Metsera, Compass, Kenvue, Fox & more

Check out the companies making headlines before the opening bell : Metsera , Pfizer — The weight-loss drugmaker soared 60% after an announcement it would be bought by Pfizer for $4.9 billion in cash. The deal is expected to close in the fo... Full story

Yahoo Finance • 3 months ago

Vinay Prasad, back at FDA, becomes chief medical and scientific officer -- again

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers Vinay Prasad, a top US FDA official who left [https://seekingalpha.com/news/4474009-fda-vaccines-head-chief-medical-officer-vinay-prasad-departs-agency]the agency in la... Full story

Yahoo Finance • 3 months ago

Benjamin Graham Detailed Fundamental Analysis - SRPT

Below is Validea's guru fundamental report for SAREPTA THERAPEUTICS INC (SRPT). Of the 22 guru strategies we follow, SRPT rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value met... Full story

Yahoo Finance • 3 months ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Value investing subreddit by Significant-Foot3928. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.'s share was trading at $... Full story

Yahoo Finance • 3 months ago

Sarepta Therapeutics (SRPT) Fell Despite Reporting Good Results

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Mid-cap stocks rebounded in the second quarter,... Full story

Yahoo Finance • 3 months ago

SRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class Action

SAN DIEGO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22,... Full story